B7-H3 drug for recurrent brain tumor or brain metastases
Part of Cancer clinical trials.
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a glioblastoma that has grown or returned after standard treatments, or you have a brain metastasis that needs surgery.
- You have tumor tissue from a prior biopsy or surgery that can be tested.
- You are age 18 or older.
- You are well enough to do daily activities on your own (ECOG score 0-2).
- Your blood cell counts, liver, kidney, and clotting function are within safe ranges.
- You are not pregnant, breastfeeding, and agree to use effective birth control during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests an oral medication (JBI-778) for people with brain metastases or certain brain tumors that have not responded to standard treatment. It aims to see if the drug is safe and if it can help shrink or stabilize the disease.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a stronger combination of treatments given after surgery for people with glioblastoma (GBM) that was only partially removed or that starts growing again quickly. It aims to see if this approach can help control the tumor better. You may be eligible if you are newly diagnosed, over 18, have good organ function, and do not have other serious health issues.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.